Cargando…
MBCL-36. HOW TO INCREASE SURVIVAL IN 7 TO 10% OF PATIENTS WITH AVERAGE-RISK MEDULLOBLASTOMA WITHOUT NEW THERAPIES: EARLY PROSPECTIVE NEURORADIOLOGY SCREENING EXPERIENCE FROM THE CHILDREN’S ONCOLOGY GROUP
BACKGROUND: Previous Children’s Oncology Group (COG) average-risk medulloblastoma studies retrospectively identified that 7 to 10% of patients were wrongly staged; either due to the presence of unequivocal residual disease greater than 1.5cm(2) or metastatic disease. Notably, these patients had an i...
Autores principales: | Gottardo, Nicholas, Leary, Sarah, Kang, Guolian, Gossett, Jeffrey, Fouladi, Maryam, Kessel, Sandy, Sabin, Noah, Jaju, Alok, Harreld, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715223/ http://dx.doi.org/10.1093/neuonc/noaa222.512 |
Ejemplares similares
-
MBCL-34. EFFICACY OF METHOTREXATE (MTX) ACCORDING TO MOLECULAR SUB-TYPE IN YOUNG CHILDREN WITH MEDULLOBLASTOMA (MB): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334
por: Mazewski, Claire, et al.
Publicado: (2020) -
MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
por: Leary, Sarah, et al.
Publicado: (2020) -
MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331
por: Michalski, Jeff, et al.
Publicado: (2020) -
MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
por: Robinson, Giles W, et al.
Publicado: (2020) -
MBCL-52. ENDOCRINE PROFILE AFTER MEDULLOBLASTOMA TREATMENT
por: Pavon-Mengual, Miriam, et al.
Publicado: (2020)